Hyperprolactinaemia

Journal of Obstetrics and Gynaecology

Volumn 27, Issue 5, 2007, Pages 455-459

  Patel, S S ^a,c   Bamigboye, V ^b  

^a ROYAL BOLTON HOSPITAL   (United Kingdom)

^b FURNESS GENERAL HOSPITAL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Hyperprolactinaemia; Macroadenoma; Microadenoma; Prolactin; Prolactinoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE; ESTROGEN; FOLLITROPIN; LISURIDE; PERGOLIDE; PREDNISOLONE; PROLACTIN; QUINAGOLIDE; RALOXIFENE; TESTOSTERONE; THYROXINE;

ABDOMINAL CRAMP; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CRANIOPHARYNGIOMA; DIZZINESS; DOPAMINE RELEASE; DRUG INDUCED HEADACHE; FATIGUE; FOLLITROPIN BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSITIS; IMMUNOREACTIVITY; KIDNEY CARCINOMA; KIDNEY METASTASIS; NAUSEA; NEGATIVE FEEDBACK; NOSE CONGESTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTIN SYNTHESIS; REVIEW; VOMITING;

ADENOMA; DOPAMINE AGONISTS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERPROLACTINEMIA; NEUROSURGICAL PROCEDURES; PITUITARY NEOPLASMS; PROLACTINOMA; RADIOTHERAPY;

EID: 34548103015     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.1080/01443610701406125     Document Type: Review

References (18)

1. Brada M, Ajithkuma TV, Minniti G. 2004. Radiosurgery for pituitary adenomas. Clinical Endocrinology 61:531-543.
2. Buvat J. 2003. Hyperprolactinemia and sexual function in men: a short review. International Journal of Impotence Research 15:373-377.
3. Cheng WC, Yen ML, Hsu SH, Chen KH, Tsai KS. 2004. Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women. Endocrine 23:215-218.
4. Czeizel A, Kiss R, Racz K, Mohori K, Glaz E. 1989. Case-control cytogenetic study in offspring of mothers treated with Bromocriptine during early pregnancy. Mutation Research 210:23-27.
5. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. 1994. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Annals of International Medicine 120:817-820.
6. Hoffman KL, Parsons GH, Allerdt LJ, Brooks JM, Miles LEM. 1984. Elimination of 'hook-effect' in two-site immunoradiometric assays by kinetic rate analysis. Clinical Chemistry 30:1499-1501.
7. Karunakaran S, Page RC, Wass JA. 2001. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clinical Endocrinology (Oxf) 54:295-300.
8. Lee SJ, Yoo HJ, Park SW, Choi MG. 2004. A case of cystic lymphocytic hypophysitis with cacosmia and hypopituitarism. Endocrinology Journal 51:375-380.
9. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. 2002. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. Journal of Clinical Endocrinology and Metabolism 87:3180-3186.
10. Miller KK. 2004. Management of hyperprolactinemia in patients receiving antipsychotics. CNS Spectrums 9:S28-S32.
11. Molitch ME. 1985. Pregnancy and the hyperprolactinaemic woman. New England Journal of Medicine 312:1362.
12. Patel DD, Bhatavdekar JM, Chikhlikar PR, Ghosh N, Suthar TP, Shah NG et al. 1996. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. Journal of Surgical Oncology 62:86-92.
13. Peeva E, Venkatesh J, Michael D, Diamond B. 2004. Prolactin as a modulator of B cell function: implications for SLE. Biomedicine and Pharmacotherapy 58:310-319.
14. Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A et al. 2002. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reproductive Toxicology 16:791-793.
15. Saraiya H. 2003. Postburn galactorrhoea with refractory hypertrophic scars: role of obesity under scrutiny. Journal of Burn Care Rehabilitation 24:392-394.
16. Schofl C, Schofl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JS et al. 2002. Falsely low serum prolactin in two cases of invasive macroprolactinomas. Pituitary 5:261-265.
17. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A et al. 2002. Macroprolactinemia revisited: a study on 106 patients. Journal of Clinical Endocrinology and Metabolism 87:581-588.
18. Wallaschofski H, Kobsar A, Sokolova O, Siegemund A, Stepan H, Faber R et al. 2004. Differences in platelet activation by prolactin and leptin. Hormone and Metabolic Research 36:453-457.